Wisevoter
U.S.

Actinium Pharmaceuticals Names Matt David New CFO

The clinical-stage firm recruits a former CorMedix executive to oversee its financial and capital market strategy.

Updated on Oct. 15, 2026 in Corporate Finance

Isometric editorial illustration of a modern pharmaceutical research building in muted teal and cream, representing corporate growth in clinical drug development.
Actinium Pharmaceuticals has appointed Matt David, formerly of CorMedix Inc., as its new chief financial officer to oversee financial and capital strategies. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to successfully navigate their financial operations during complex drug development stages?

Actinium Pharmaceuticals has appointed Matt David as its new Chief Financial Officer. In this role, he will manage the company's finance, accounting, capital markets, and investor relations departments.

Why it matters

This executive appointment comes as Actinium Pharmaceuticals advances its clinical programs, including the Actimab-A pipeline which is moving toward a Phase 2/3 trial.

Actinium Pharmaceuticals maintains a portfolio of approximately 250 patents and patent applications. The company is currently focused on the development of the ATNM-400, Actimab-A, and Iomab-ACT therapeutic programs.

The players

Actinium Pharmaceuticals

This is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with high unmet medical needs.

Matt David

He is a finance executive and physician who previously served as the Executive Vice President and Chief Business Officer at CorMedix Inc.

CorMedix Inc.

This biopharmaceutical company focuses on developing and commercializing therapeutic products for patients with kidney disease and other conditions.

The details

Matt David, who holds a medical degree from the NYU School of Medicine, takes over as the principal financial officer after a tenure at CorMedix Inc. His background includes overseeing the 2023 FDA approval and 2024 commercial launch of the drug DefenCath, as well as a 2025 acquisition.

Timeline

  1. Matt David joined CorMedix in 2020.

  2. CorMedix received FDA approval for DefenCath in 2023.

  3. CorMedix launched DefenCath commercially in 2024.

  4. CorMedix acquired a commercial anti-infectives company in 2025.

  5. Actinium Pharmaceuticals announced the appointment on October 15, 2026.

Market Dynamics

This leadership transition is part of a broader industry shift where biotech firms are prioritizing financial expertise to navigate the complex capital requirements of late-stage clinical trials. By aligning experienced leadership with the Actimab-A Phase 2/3 trial, the company positions itself to better manage the high-cost transition from R&D to potential commercialization.

Shareholders and potential investors should monitor how the new CFO manages the company's capital markets strategy during the critical Phase 2/3 trial phase. The success of this transition may influence future liquidity and the company's ability to sustain long-term research programs.

The takeaway

Bringing in an executive with both medical training and commercial launch experience indicates a strategic pivot toward operational maturity. Investors often look for this specific blend of clinical understanding and financial rigor when evaluating a company's ability to reach late-stage milestones.

Further reading

For more on industry leadership trends, visit Corporate Finance.

Live Poll

Do you trust pharmaceutical companies to successfully navigate their financial operations during complex drug development stages?